loading page

Cardiotoxicity and pharmacogenetics of doxorubicin in black Zimbabwean breast cancer patients
  • +3
  • Vincent Nyangwara,
  • Tinashe Mazhindu,
  • Zedias Chikwambi,
  • Collen Masimirembwa,
  • Margaret Borok,
  • Ntokozo Ndlovu
Vincent Nyangwara
African Institute of Biomedical Science and Technology

Corresponding Author:vinakech@gmail.com

Author Profile
Tinashe Mazhindu
University of Zimbabwe Faculty of Medicine
Author Profile
Zedias Chikwambi
African Institute of Biomedical Science and Technology
Author Profile
Collen Masimirembwa
AiBST
Author Profile
Margaret Borok
University of Zimbabwe Faculty of Medicine
Author Profile
Ntokozo Ndlovu
University of Zimbabwe Faculty of Medicine
Author Profile

Abstract

AIMS Doxorubicin-induced cardiotoxicity (DIC) is a significant cause of mortality in cancer care. This study was conducted to establish the frequency of DIC in Zimbabwean breast cancer patients on doxorubicin and to test the DIC predictive power of genetic biomarkers. METHODS A cohort of 50 Zimbabwean breast cancer patients treated with doxorubicin were followed up for 12 months with serial echocardiography and genotyped for UGTA1A6*4, SLC28A3 and RARG. 11% of the patients experienced DIC. RESULTS The frequency of SLC28A3 (rs7853758), UGT1A6*4 (rs17863783) and RARG (rs2229774) was 60.7%, 17.9% and 14.3% respectively. No association between DIC and the three variants was observed. CONCLUSIONS This is the first study on the prevalence of DIC and associated genetic biomarker predictive evaluation in Zimbabwean breast cancer patients. The genetic frequencies observed in our study was different to that reported in other populations. A larger sample size with a longer follow up time will be necessary in future studies.
22 Sep 2022Submitted to British Journal of Clinical Pharmacology
27 Sep 2022Assigned to Editor
27 Sep 2022Submission Checks Completed
03 Oct 2022Reviewer(s) Assigned
18 Oct 2022Review(s) Completed, Editorial Evaluation Pending
28 Oct 2022Editorial Decision: Revise Major